Delving into the Latest Updates on REGN-22044 with Synapse

Overview

Basic Info

Drug Type

Unknown

Synonyms

REGN-22044

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Regeneron Pharmaceuticals, Inc.

Active Organization

Regeneron Pharmaceuticals, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

This clinical study will evaluate the study drug, REGN22044, in healthy participants. REGN22044 has not previously been studied in humans.
The purpose of this study is to learn:
* What side effects may happen when REGN22044 is taken
* How much of REGN22044 is in the blood at different times
* Whether the body makes antibodies against REGN22044 (which could make the drug less effective or could lead to side effects)

Start Date07 May 2026

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

100 Clinical Results associated with REGN-22044

Login to view more data

100 Translational Medicine associated with REGN-22044

Login to view more data

100 Patents (Medical) associated with REGN-22044

Login to view more data

100 Deals associated with REGN-22044

Login to view more data